HCL-TECHNOLOGIES
21.2.2017 21:18:05 CET | Business Wire | Press release
Three winners of HCL Grant 2017 across categories of Environment, Health and Education were today announced at a ceremony held at HCL Technologies Hub, Noida. Shri Arun Jaitley, Hon’ble Union Minister of Finance and Corporate Affairs , presided over the ceremony as the Chief Guest and felicitated the winners. Each winning NGO receives a Grant of up to INR 5 crores.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170221006559/en/
At the occasion, Shri Arun Jaitley also released a compendium titled “The Fifth Estate - NGOs transforming Rural India in Environment, Health and Education ,” which is a compilation of all the finalists of the second edition of HCL Grant.
Shri Arun Jaitley, Hon’ble Union Minister of Finance and Corporate Affairs, congratulated the winners of HCL Grant 2017 and appreciated the work of HCL and the jury.
Addressing the gathering he said , “I must compliment HCL for going into the larger society, creating an independent jury, looking at areas which need support and getting the jury to select the best so that the winners can be role models for others.”
Malcolm Gladwell , an eminent author and speaker, attended the ceremony as a Special Guest and addressed the gathering comprising Board members, senior leadership and other distinguished guests from various walks of life.
The winning NGOs across three categories are:
- Environment - Foundation of Ecological Security (Gujarat)
- Health - Child in Need Institute (CINI) (West Bengal)
- Education - MelJol (Maharashtra)
Ms. Robin Abrams, Chairperson of Jury, HCL Grant, said, “HCL Grant is so much more than the fund itself. The mark of the strategic value of any grant is leverage. From the focus on governance and sustainability, sharing of best practices and how corporates and their employees can engage with NGOs – HCL Grant delivers on strategic value for the NGOs of India and for India’s Fifth Estate. It is exciting to be a part of this kind of leverage.”
HCL Grant, a CSR commitment by HCL through HCL Foundation, envisions to contribute to rural development by strengthening NGOs through deep institutional involvement and commitment. The Grant stands testimony to the fact that only strong governance structures management capabilities and reliable impact measurement systems within NGOs can help them take up and sustain high impact, complex and social transformational projects.
The winning NGOs have been selected by an eminent jury panel. Members of the panel are Ms. Robin Abrams – Former President of Palm Computing, and the longest serving Board member of HCL Technologies; Dr. Isher Judge Ahluwalia - Leading Economist and Chairperson, Board of Governors, the Indian Council for Research on International Economic Relations; Ms. Pallavi Shroff - Eminent Legal Counsel, Shardul Amarchand Mangaldas & Co.; Mr. B.S. Baswan - Former Director, Indian Institute of Public Administration; Mr. Richard Lariviere - President, Field Museum, Chicago and Former President of the University of Oregon; Dr. John E. Kelly – Senior Vice President, Cognitive Solutions and Research, IBM Corporation; and Mr. Shiv Nadar – Founder & Chairman, HCL and Shiv Nadar Foundation.
For more information please visit www.hcltech.com/HCL-Grant .
View source version on businesswire.com: http://www.businesswire.com/news/home/20170221006559/en/
Contact:
HCL Technologies
Ajay Davessar, +91 120 43828280
VP & Global
Head - Corporate Communications
Ajay.davessar@hcl.com
Link:
Social Media:
https://www.facebook.com/https://www.facebook.com/HCLTechnologies
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
